BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 28288848)

  • 1. BCL11B-Mediated Epigenetic Repression Is a Crucial Target for Histone Deacetylase Inhibitors in Cutaneous T-Cell Lymphoma.
    Fu W; Yi S; Qiu L; Sun J; Tu P; Wang Y
    J Invest Dermatol; 2017 Jul; 137(7):1523-1532. PubMed ID: 28288848
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Histone deacetylase inhibitors inhibit metastasis by restoring a tumor suppressive microRNA-150 in advanced cutaneous T-cell lymphoma.
    Abe F; Kitadate A; Ikeda S; Yamashita J; Nakanishi H; Takahashi N; Asaka C; Teshima K; Miyagaki T; Sugaya M; Tagawa H
    Oncotarget; 2017 Jan; 8(5):7572-7585. PubMed ID: 27935859
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MicroRNA-16 mediates the regulation of a senescence-apoptosis switch in cutaneous T-cell and other non-Hodgkin lymphomas.
    Kitadate A; Ikeda S; Teshima K; Ito M; Toyota I; Hasunuma N; Takahashi N; Miyagaki T; Sugaya M; Tagawa H
    Oncogene; 2016 Jul; 35(28):3692-704. PubMed ID: 26640145
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Preclinical Studies Support Combined Inhibition of BET Family Proteins and Histone Deacetylases as Epigenetic Therapy for Cutaneous T-Cell Lymphoma.
    Zhao L; Okhovat JP; Hong EK; Kim YH; Wood GS
    Neoplasia; 2019 Jan; 21(1):82-92. PubMed ID: 30529073
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Aberrant expression of BCL11B in mycosis fungoides and its potential role in interferon-induced apoptosis.
    Gu X; Wang Y; Zhang G; Li W; Tu P
    J Dermatol; 2013 Aug; 40(8):596-605. PubMed ID: 23682716
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Novel cell adhesion/migration pathways are predictive markers of HDAC inhibitor resistance in cutaneous T cell lymphoma.
    Andrews JM; Schmidt JA; Carson KR; Musiek AC; Mehta-Shah N; Payton JE
    EBioMedicine; 2019 Aug; 46():170-183. PubMed ID: 31358475
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synergistic interaction of the histone deacetylase inhibitor SAHA with the proteasome inhibitor bortezomib in cutaneous T cell lymphoma.
    Heider U; Rademacher J; Lamottke B; Mieth M; Moebs M; von Metzler I; Assaf C; Sezer O
    Eur J Haematol; 2009 Jun; 82(6):440-9. PubMed ID: 19220424
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Kinome profiling analysis identified Src pathway as a novel therapeutic target in combination with histone deacetylase inhibitors for cutaneous T-cell lymphoma.
    Jimura N; Fujii K; Qiao Z; Tsuchiya R; Yoshimatsu Y; Kondo T; Kanekura T
    J Dermatol Sci; 2021 Mar; 101(3):194-201. PubMed ID: 33531202
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Analysis of STAT4 expression in cutaneous T-cell lymphoma (CTCL) patients and patient-derived cell lines.
    Litvinov IV; Cordeiro B; Fredholm S; Ødum N; Zargham H; Huang Y; Zhou Y; Pehr K; Kupper TS; Woetmann A; Sasseville D
    Cell Cycle; 2014; 13(18):2975-82. PubMed ID: 25486484
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Romidepsin and Azacitidine Synergize in their Epigenetic Modulatory Effects to Induce Apoptosis in CTCL.
    Rozati S; Cheng PF; Widmer DS; Fujii K; Levesque MP; Dummer R
    Clin Cancer Res; 2016 Apr; 22(8):2020-31. PubMed ID: 26660520
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Histone deacetylase inhibitors potentiate photochemotherapy in cutaneous T-cell lymphoma MyLa cells.
    Sung JJ; Ververis K; Karagiannis TC
    J Photochem Photobiol B; 2014 Feb; 131():104-12. PubMed ID: 24518645
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Current Status of HDAC Inhibitors in Cutaneous T-cell Lymphoma.
    Lopez AT; Bates S; Geskin L
    Am J Clin Dermatol; 2018 Dec; 19(6):805-819. PubMed ID: 30173294
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synergy of BCL2 and histone deacetylase inhibition against leukemic cells from cutaneous T-cell lymphoma patients.
    Cyrenne BM; Lewis JM; Weed JG; Carlson KR; Mirza FN; Foss FM; Girardi M
    Blood; 2017 Nov; 130(19):2073-2083. PubMed ID: 28972015
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Therapeutic Potential of AN-7, a Novel Histone Deacetylase Inhibitor, for Treatment of Mycosis Fungoides/Sezary Syndrome Alone or with Doxorubicin.
    Moyal L; Feldbaum N; Goldfeiz N; Rephaeli A; Nudelman A; Weitman M; Tarasenko N; Gorovitz B; Maron L; Yehezkel S; Amitay-Laish I; Lubin I; Hodak E
    PLoS One; 2016; 11(1):e0146115. PubMed ID: 26752418
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combination of retinoid and histone deacetylase inhibitor produced an anti-tumor effect in cutaneous T-cell lymphoma by restoring tumor suppressor gene, retinoic acid receptorβ2, via histone acetylation.
    Kato Y; Egusa C; Maeda T; Tsuboi R
    J Dermatol Sci; 2016 Jan; 81(1):17-25. PubMed ID: 26596218
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mechanism, Consequences, and Therapeutic Targeting of Abnormal IL15 Signaling in Cutaneous T-cell Lymphoma.
    Mishra A; La Perle K; Kwiatkowski S; Sullivan LA; Sams GH; Johns J; Curphey DP; Wen J; McConnell K; Qi J; Wong H; Russo G; Zhang J; Marcucci G; Bradner JE; Porcu P; Caligiuri MA
    Cancer Discov; 2016 Sep; 6(9):986-1005. PubMed ID: 27422033
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Selective induction of apoptosis by histone deacetylase inhibitor SAHA in cutaneous T-cell lymphoma cells: relevance to mechanism of therapeutic action.
    Zhang C; Richon V; Ni X; Talpur R; Duvic M
    J Invest Dermatol; 2005 Nov; 125(5):1045-52. PubMed ID: 16297208
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical Efficacy of Romidepsin in Tumor Stage and Folliculotropic Mycosis Fungoides.
    Foss F; Duvic M; Lerner A; Waksman J; Whittaker S
    Clin Lymphoma Myeloma Leuk; 2016 Nov; 16(11):637-643. PubMed ID: 27637428
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Robust Tumoricidal Effects of Combined BET/HDAC Inhibition in Cutaneous T-Cell Lymphoma Can Be Reproduced by ΔNp73 Depletion.
    Zhao L; Hsiao T; Stonesifer C; Daniels J; Garcia-Saleem TJ; Choi J; Geskin L; Rook AH; Wood GS
    J Invest Dermatol; 2022 Dec; 142(12):3253-3261.e4. PubMed ID: 35787399
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mass spectrometry and DigiWest technology emphasize protein acetylation profile from Quisinostat-treated HuT78 CTCL cell line.
    Méhul B; Perrin A; Grisendi K; Galindo AN; Dayon L; Ménigot C; Rival Y; Voegel JJ
    J Proteomics; 2018 Sep; 187():126-143. PubMed ID: 30012418
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.